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ABSTRACT
Integrating vectors such as viruses and transposons
insert transgenes semi-randomly and can potentially
disrupt or deregulate genes. For these techniques to
be of therapeutic value, a method for controlling the
precise location of insertion is required. The
piggyBac (PB) transposase is an efficient gene
transfer vector active in a variety of cell types and
proven to be amenable to modification. Here we
present the design and validation of chimeric PB
proteins fused to the Gal4 DNA binding domain with
the ability to target transgenes to pre-determined
sites. Upstream activating sequence (UAS) Gal4
recognition sites harbored on recipient plasmids
were preferentially targeted by the chimeric Gal4–
PB transposase in human cells. To analyze the
ability of these PB fusion proteins to target chromo-
somal locations, UAS sites were randomly integrated
throughout the genome using the Sleeping Beauty
transposon. Both N- and C-terminal Gal4-PB fusion
proteins but not native PB were capable of targeting
transposition nearby these introduced sites. A
genome-wide integration analysis revealed the
ability of our fusion constructs to bias 24%of integra-
tions near endogenous Gal4 recognition sequences.
This work provides a powerful approach to enhance
the properties of the PB system for applications such
as genetic engineering and gene therapy.
INTRODUCTION
The ability of integrating vectors to permanently intro-
duce foreign genes into chromosomes has resulted in
major advances in the fields of genetic engineering, func-
tional genomics and gene therapy. For these techniques to
be of value in the clinical setting it is imperative that
insertions occur at known safe loci in order to avoid
deregulation of the cell due to deleterious integrations
and to control expression of transgenes. Commonly used
viral vectors have been shown to preferentially insert their
cargo near transcriptional start sites (1–3) and there has
been increasing concern for the implications of insertional
mutagenesis (4–6). Thus, the safety of insertional therapies
would be improved by the ability to target vector integra-
tion to a specific genomic safe harbor.
Cys2His2 zinc finger proteins (ZFPs) can bind to specific
sequences by inserting an alpha-helix into the major
groove of the DNA double helix. These DNA binding
domains (DBDs) are specific for 6–18 bp DNA sites and
can now be easily designed in a few weeks and be made to
target almost any location in the genome (7–11).
By fusing ZFPs to activator or repressor domains, novel
zinc finger effectors have been used to up-regulate or
down-regulate transcription (12–15). Recently, zinc
finger nucleases (ZFNs), chimeric proteins that consist
of a ZFP and a Fok1 nuclease domain, have proven to
be effective in a variety of applications such as gene dis-
ruption, transgene integration and the generation of
knockout mice (16–20). By inducing targeted double-
stranded breaks (DSBs) and using the host cell’s repair
machinery, ZFNs have been used to cause intentional
mutations or insert whole genes at the respective targets
(21–24). However, the nuclease component of ZFNs can
cause off-target cleavage events that result in undesired
mutations. Concerns about cyto and genotoxicity remain
significant obstacles to be overcome for this to be a safe
strategy (16,25–28).
An alternative approach has been to directly fuse DNA
integrating enzymes to ZFPs in an attempt to localize
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activity of the vector to a specific genomic location (29).
For example, ZFP-HIV-1 integrase fusions packaged in
virions showed promise with preferential targeting in
both plasmids and genomic DNA (gDNA), albeit at low
levels (30–34). Programmable recombinases using zinc
fingers bound to a catalytic domain have been shown to
precisely integrate transgenes at pre-determined sites
(35–38). However, the catalytic domains for these
proteins are sequence-specific, thus targeting is limited to
sites containing the required sequences. Steps have been
taken to alter the sequence specificity of these catalytic
domains in order to allow integration into novel sites
(39,40).
Kaminski et al. suggested using transposases fused to a
DBD as a method for directing transgene insertion and it
was shown previously that modifications to the yeast
retrotransposase Ty5 could influence its target selection
profile (41–44). Others have shown in Escherichia coli
that the ISY100 transposase bound to a ZFP from the
mouse transcription factor Zif268 could target transgenes
near the expected binding site on recipient plasmids 48%
of the time (45). In addition, the prokaryotic mobile
element IS30 fused to the Gli1 transcription factor is
able to target extrachromosomal plasmids in zebrafish
embryos (46).
The Sleeping Beauty (SB) transposase has shown activity
in mammalian cells and has been used for diverse non-viral
applications (47–49).However, the direct fusionofDBDs to
SB has lead to complete or significant reductions in
transposase activity (50–52). Despite this, Yant et al.
demonstrated DBD–SB fusion protein-mediated transgene
targeting at efficiencies of 18–33% to specific sites within
plasmids in human cells. However, this groupwas unable to
detect targeted integration when coupling SB with a DBD
specific to an endogenous chromosomal location.
The piggyBac (PB), an insect transposase isolated from
the moth Trichoplusia Ni, is highly efficient in a broad
range of organisms including yeast and mouse, as well
as human cell lines and is able to integrate relatively
large cassettes of >100 kb. PB inserts transgenes at
TTAA tetranucleotide sites and the transposase has been
shown to be able to excise the transposon without leaving
a DNA footprint (53–64). Previously, we have shown that
PB is amenable to a Gal4 DBD fusion with little loss in
activity (50). Furthermore, we demonstrated targeting to a
plasmid recipient harboring the upstream activating
sequence (UAS) Gal4 recognition site in Aedes aegypti
embryos (65,66).
A wide range of applications would directly benefit
from safe targeted transgenic insertion. We have tested
both N- and C-terminal fusions of the classic Gal4 DBD
to the PB transposase and assessed for targeted integra-
tion in human cells near the UAS DNA binding sequence
in a genomic setting. The aim of our experiments was to
demonstrate the ability of a chimeric PB transposase fused
to a DBD to target the genome. This proof of principle is
important for transposition research and will serve as a
basis for future improvements that one day may lead to
safer transpositional gene therapy treatments in a clinical
setting.
MATERIALS AND METHODS
Plasmid development
ThemammaliancodonbiasedPB transposasewasagift from
Dr Allan Bradley. The backbone for all PB plasmids was the
self-inactivating, helper-independent pmGENIE-plasmid
system described earlier (58). The Gal4 DBD, (amino acids:
KLLSSIEQACDICRLKKLKCSKEKPKCAKCLKNN-
WEC RYSPKTKRSPLTRAHLTEVESRLERLEQLFL
LFPREDLDMILKMDSLQDIKALLTGLFVQDNVN-
KDAVTDRLASVETDMPLTLRQHRISATSSSEESSN
KGQRQLTVS) was introduced via homologous recom-
bination along with the linker: KLGGGAPAVGGGPK
(65). The transgene for all pmGENIE constructs was a
PCR amplified fragment from pERV3 (Agilent
Technologies), including the bacterial and eukaryotic pro-
moter-driven neomycin gene. This fragment was
TA-cloned into the pENTR1a vector (Invitrogen) that
had been digested with HincII and EcoRI and then
t-tailed using a terminal transferase (New England
Biolabs). The ligation product, including the neomycin
gene, was Gateway (Invitrogen) recombineered between
the attR sites in the pmGENIE plasmid transposon.
The CMV-SB11 helper plasmid was a gift from Dr
Perry Hackett. To create the SB UAS donor plasmid
pT2/HB cam UAS hygro, we used an intermediate
plasmid (pELO4) that contains the chloramphenicol
gene. The UAS site was isolated from the pGDV1-UAS
plasmid by restriction digestion with HindIII and BamHI
(65), and cloned into the pELO4 vector adjacent to its
chloramphenicol gene. Two identical 650-bp TTAA rich
regions, custom synthesized from GenScript and excised
from the pUC57 shuttle vector using BamHI or HindIII,
were ligated to both sides of the UAS target sequence to
make pELO4 cam TTAA-region UAS TTAA-region. The
hygromycin gene from pEGSH (Agilent Technologies)
was PCR amplified and ligated into the pT2/HB SB
donor plasmid with BglII and HindIII and a unique
NheI site was introduced with the PCR primers used.
The pT2/HB hygro construct was linearized with NheI
and a pELO4 PCR product, including cam, UAS and
TTAA-rich regions, was added via In-Fusion (Clontech).
This plasmid was then used to generate hygromycin resist-
ant cell lines containing the SB transposon and UAS. The
UAS-negative control SB donor plasmid was made by
PCR amplifying all but the UAS site from the pT2/HB
cam UAS hygro construct. This inverse PCR product was
re-ligated to form the control plasmid, which retained the
TTAA-rich regions but had the UAS removed.
The pT2/HB cam UAS hygro construct was reduced in
size by self-ligation using XmnI and SmaI, and used as
the recipient in the plasmid into plasmid experiment. In
order to eliminate false positives during the plasmid into
plasmid assay, the bacterial suicide ccdB gene was added
to the backbone of the pmGENIE plasmids by
In-Fusion. This strategy prevented recovery of double
resistant colonies that contained delivery plasmid
backbone resulting from non-transpositional insertion.
All restriction enzymes were purchased from New
England Biolabs.
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Cell transfections
Human embryonic kidney (HEK293) cells were main-
tained in complete DMEM supplemented with 10% heat
inactivated FBS (Invitrogen) and prior to transfection,
0.5 105 cells per well were seeded in 12-well plates. To
make the SB UAS and SB control cell lines lacking a
UAS, 100 ng of CMV-SB11 helper and 200 ng of the ap-
propriate pT2/HB SB donor plasmid were transfected
using FuGene6 (Roche Applied Science) into cells at
90% confluency. Stable cell lines were obtained after 30
days of culture in 100 mg/ml HygromycinB (Invitrogen)
and were cultured for an additional 3 weeks. We subjected
these stable SB transposon containing cell lines to a
second round of transfection with 400 ng of helper-
independent pmGENIE construct containing the
neomycin selection cassette within the transposon.
pmGENIE constructs with N- or C-terminal Gal4 fusion
or native PB were transfected in triplicates into two
independent SB UAS cell lines. Stable G418 resistant
lines were obtained after 30 days and equal numbers of
cells for each experiment were pelleted and frozen.
Genomic DNA was isolated using the DNeasy kit
(Qiagen) following the manufacturer’s protocol. A
standard colony count assay was performed using all
three constructs and a transposase-negative control as
described previously (58).
Plasmid into plasmid assay
HEK293 cells were transfected with 750 ng each of UAS
recipient plasmid pT2/HB cam UAS hygro and
helper-independent pmGENIE delivery plasmids contain-
ing either of Gal4–PB fusions or native PB. Cells were
grown without selection for 3 days, then pelleted and
episomal plasmids were isolated using the Zyppy
plasmid miniprep kit (Zymo Research). Lucigen 10G
Elite E. coli cells were electroporated with the isolated plas-
mid DNA and plated on double antibiotic camR/kanR
plates for selection. Colonies were screened by duplex
PCR to simultaneously confirm the integration of the
delivery neomycin transposon, as well as the excision of
the transposon from the backbone of the delivery
pmGENIE plasmid. Plasmid DNA from positive double
antibiotic resistant colonies was purified by miniprep and
sequenced using the primer PB 5TRE: ACG GAT TCG
CGC TAT TTA GA that extends from the PB transposon
into the adjacent sequence. Obtained sequences were
aligned to the recipient plasmid pT2/HB cam UAS
hygro to determine the insertion site and distance from
the UAS site. The efficiency by which PB delivery trans-
posons were integrated into recipient SB plasmids by the
respective PB transposase was calculated by dividing the
total number of correctly aligned sequences recovered by
the percent of colonies screened. The percent of colonies
screened was calculated by dividing the total number of
colonies PCR screened by the total colony count. (n=3,
mean±standard deviation) Statistics include two-sided,
two-sample Student’s t-test assuming equal variance
P=0.01.
Targeted genomic integration site recovery
Genomic DNA was extracted from pooled clones of stably
double-transfected HEK293 cells and nested PCR was
performed using forward primers designed to extend
from either terminal repeat element (TRE) of the
delivery PB transposon, whereas the reverse primers
were designed to the SB UAS transposon target.
Because of the repetitive nature of the UAS and surround-
ing sequence we did not obtain PCR products extending
through the UAS and therefore designed two sets of
reverse primers to identify insertions upstream and down-
stream of the UAS. See Supplementary Table S1 for
primer sequences. Primary PCR products obtained using
KOD Xtreme Hot Start DNA Polymerase (Novagen)
were diluted 1:100 in H2O and used as template for
nested PCR using Easy-A High-Fidelity Polymerase
(Agilent Technologies). Amplification products were
either first gel purified with Zymoclean Gel DNA
Recovery Kit (Zymo Research) or directly TA-cloned
into the pGEM-T Easy Vector (Promega). Unique
clones were verified by colony PCR, plasmid DNA was
purified by miniprep and then sequenced with Sp6 or T7
primers. Sequences were aligned to the SB UAS trans-
poson and distance to the UAS and exact insertion site
locations were recorded.
Copy number assay
Monoclonal expansions of double-resistant hygromycin/
G418 HEK293 cells that had been first transfected with
SB UAS (pT2/HB cam UAS hygro) then with N- or
C-terminal Gal4–PB, or PB control pmGENIE plasmids
(n=5 each) were seeded into 96-well plates at low density
and visually verified. gDNA from expanded clones was
isolated for Southern blot and quantitative PCR (qPCR)
copy number assay. In order to standardize the qPCR
copy number assay, a Southern blot was performed to
identify a known number of insertions for representative
PB and SB experiments. Genomic DNA was isolated
using the DNeasy kit (Qiagen) following the manufac-
turer’s protocol. A quantity of 20 mg of each sample was
digested overnight using 10 U of HindIII per microgram
of gDNA. A quantity of 12 mg of digested gDNA was run
for 75 h on a 1% agarose gel at 15V. The gDNA was then
blotted to a Hybond+nylon membrane (GE Healthcare)
for 12 h and processed for hybridization. A DIG-labeled
probe was generated by PCR amplification using the PCR
DIG Probe Synthesis Kit (Roche Applied Science) and the
following primers: PB Southern Forward ACGTAAACG
GCCACAAGTTC, PB Southern Reverse TGC-TCAGGT
AGTGGTTGTCG. SB Southern Forward AACTCGTTT
TTCAACTACTCC-ACA, SB Southern Reverse ACTGT
CGGGCGTACACAAAT. PCR parameters used: initial
denaturation at 94C for 2min, 35 cycles of 30 s denatur-
ation at 94C, 30 s annealing at 56C and 1min elongation
at 72C, with a final elongation for 10min. Hybridization
was performed overnight at 55C using the DIG Easy Hyb
Kit, (Roche Applied Science) and were processed accord-
ing to the manufacturer’s protocol. Chemiluminescent
signals were visualized with an LAS-3000 imaging
system (Fujifilm).
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The qPCR copy number assays were performed by
duplex Taqman real-time PCR, where one assay interro-
gates the transgene copy number, whereas the other assay
to Ribonuclease P (RNaseP) serves as a reference. Primers
and probes were custom designed (to the 50TRE for PB and
the 30TRE for SB) or pre-made (RNAseP) and were
supplied by Applied Biosystems. The primer and probe se-
quences are as follows: PB 5TRE Copy ForwardGTGACA
CTTACCGCATTGACAAG, PB 5TRE Copy ReverseGC
TGTGCATTTAGGACATCTCAGT, PB Reporter ACG
CCTCACGGGAGCTC, SB 3TRECopy ForwardCTCGT
TTTTCAACTACTCCACAAATTTCT, SB 3TRE Copy
Reverse ACAATTGTTGGAAAAATGACTTGTGTCA,
SB ReporterTTTGGCAAGTCAGTTAGGACATCTA.
The assays were performed according to the TaqMan
copy number assay protocol (Applied Biosystems) using
the Step-One-Plus real-time PCR machine in a 20 -ml
reaction volume containing 50 ng DNA. A minimum of
four replicates per sample was assayed. One sample with
known transgene copy number (as determined by Southern
blot analysis) was included. The copy number assays were
normalized to RNAseP, known to occur in two copies in
the genome (Applied Biosystems). The results were
analyzed using the software CopyCaller v1.0 (Applied
Biosystems).
Western Blotting
Cells were cultured as described. After 48 h of incubation,
cells were lysed with lysis buffer supplemented with Set III
protease inhibitors (Calbiochem). A quantity of 60 mg of
total protein was resolved on a pre-cast SDS–polyacryl-
amide gel (Bio-Rad). Expression of PB proteins was
determined by western blotting using a mouse monoclonal
anti-PB non-purified antibody. Binding of primary
antibody was detected using an anti-mouse horseradish
peroxidase-conjugated secondary antibody (Santa Cruz
Biotechnology). Bands were visualized with an LAS-3000
imaging system (Fujifilm).
Non-restrictive linear amplification-mediated PCR and
454 sequencing
For the off-target insertion analysis we adapted non-
restrictive linear amplification-mediated (LAM) PCR (67).
Briefly, 1mg of gDNA from double-resistant hygromycin/
G418 HEK293 cells for both Gal4 fusion samples, as well
as PB control (n=4 each) was used as template for linear
PCR using single primers for linear amplification extending
from the PB-TREs into flanking genomic sequence. See
Supplementary Table S2 for primer sequences. Single
stranded linkers were ligated to these linear PCR products
and nested PCR was performed to amplify the flanking
genomic sequence. GS-FLX sequencing primers were
added by PCR and samples were sequenced using a 454
GS-FLX Titanium sequencer (Life Sciences) in accordance
with the manufacturer’s protocol by the University of
Hawaii Advanced Studies in Genomics, Proteomics and
Bioinformatics (ASGPB) unit. Resulting sequences were
trimmed and de-multiplexed using CLC Genomics
Workbench version 4.7 (CLC Bio). The reads were
mapped against the human genome reference, version
GRCh37.63, using the short read alignment component
(bwa-short) of the Burrows–Wheeler Aligner (68), selecting
for reads that align over 80% of the sequence with a
minimum of 90% similarity. Distances of insertion sites to
endogenous Gal4 recognition sites were obtained using
custom scripts, which are available upon request. Gal4 rec-
ognition sequences were defined as CGGNNNNNNNNN
NNCCG and a total of 56 898 sites were identified in the
human genome. The position weight matrix for the Gal4
DBD is depicted in Supplementary Table S3. Distances to
transcriptional start sites, as well as other annotations were
obtained using the Homer bioinformatics tool (69) available
online at: http://biowhat.ucsd.edu/homer/ngs/annotation.
html. Of the 66 414 integration sites recovered using
nrLAM PCR, 7004 sites aligned to unique genomic loca-
tions. A list of all insertion sites recovered by non-restrictive
(nr) LAM PCR is available upon request.
RESULTS
Chimeric Gal4 PB directs transposition into plasmid
targets
In a previous publication, we described highly efficient PB
plasmids that maintained 92% activity of integration after
addition of the Gal4 DBD (50). Here, we have tested the
hypothesis that by tethering the PB transposase to Gal4,
we are able to target integration of transposons near UAS
recognition sites in mammalian cells. In the first set of
experiments, we used a plasmid into plasmid approach.
The recipient plasmid contained a chloramphenicol gene
(camR) and a UAS site that consisted of five recognition
sequences described earlier (65). The delivery plasmid
contained the PB transposase, with or without a Gal4
DBD and a transposon delivery cassette harboring the
neomycin (kanR) gene for bacterial selection. Integration
of the delivery cassette into the recipient plasmid
conferred double resistance to camR/kanR when trans-
formed into E. coli (Figure 1A).
The recipient and delivery plasmids were transfected
into HEK293 cells and plasmid DNA was isolated 3
days later. Total isolates were electroporated into
E. coli and plated on camR/kanR for selection. Colonies
were screened by colony PCR to confirm enzymatic
excision of the transposon from the delivery plasmid.
Plasmid DNA from positive clones was purified and
sequenced.
To identify the transposon insertion sites within the
recipient plasmid we sequenced out from the delivery
cassette into the adjoining plasmid DNA. We flanked
both sides of the UAS target with a 650-bp region in
which 65 TTAA sites were spaced 10 bp apart. This
design would allow us to analyze distance requirements
for integration from the UAS. For example, preferential
integration at a certain distance from the UAS might be
evidence for spatial protein tension during integration or
be the result of Gal4 linker length. Only sequences where
the PB TRE was immediately followed by a TTAA and
consecutively flanked by recipient sequence were con-
sidered as verified transpositional insertions. A total of
182 verified sequences were recovered for the Gal4
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fusions and native PB experiments. The efficiency of total
integrations of the chimeric Gal4 protein was over three
times that of native PB control (Figure 1B). This was
expected because the Gal4 DBD is thought to bring the
PB protein and recipient plasmid together via UAS target
binding (Figure 1A). Furthermore, an increase in total
integrations is suggestive of targeting to sites nearby the
UAS on the recipient plasmid.
By analyzing the distance of integration sites on
the recipient plasmid relative to the UAS site, we
found that 87% of N-terminal Gal4-PB (nGal4-PB)
insertions were located within a region 800 bp up- or
downstream of the UAS, whereas only 59% of the PB
control insertions fell within this region. Similarly, the
C-terminal fused PB (PB-cGal4) also had a significant
ability (77%) to integrate near the UAS site (Table 1).
More specifically, 47% of the nGal4–PB and 32% of
the PB–cGal4 directed integrations were within 250 bp
of the UAS compared with 21% for the native PB
control. In addition, 39% of these nGal4–PB mediated
insertions were detected within 250 bp upstream of the
UAS site (Figure 1C). In contrast, the PB–cGal4 sample
displayed a more evenly spaced distribution of insertion
sites. Native PB frequently integrated farther upstream
or downstream from the UAS compared with both
fusion proteins (Figure 1C). In summary, this data
shows that in our plasmid model the addition of a
Gal4 DBD to either N- or C-terminal end of the PB
protein confers a propensity for transposition near the
UAS site.
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Figure 1. (A) Schematic for the plasmid into plasmid experiment. Both the delivery plasmid containing the delivery transposon and transposase
coding sequence, as well as the recipient plasmid containing the chloramphenicol gene (camR) and the UAS were transfected into HEK293 cells. The
tethering of Gal4 to the PB transposase (red circles) is thought to restrict integration to TTAA sites found near the UAS recognition sequence.
Native PB proteins are free to integrate throughout the recipient plasmid. Delivery transposons contain the 50TRE and 30TRE for PB (purple arrows)
and the neomycin gene (Neo) and confer kanR to the recipient plasmid. Recovered camR/kanR plasmids were sequenced with PB 5TRE (black
arrows) in order to identify insertion sites. (B) Plasmid into plasmid integration efficiency of PB versus Gal4–PB. Increased total integrations into the
recipient plasmid were observed by fusing the Gal4 DBD to PB. (C) Percentages of integration sites recovered at increasing distances from the UAS.
N- and C-terminal Gal4 PB integrate closer to the UAS on the recipient plasmid compared with native PB.
6982 Nucleic Acids Research, 2012, Vol. 40, No. 14
Genomic targeting of the chimeric Gal4 PB
In order to determine whether targeting could be achieved
in a genomic setting, we used a recipient transposon
containing the UAS and TTAA-rich regions flanked by
the TREs of SB (pT2/HB cam UAS hygro). This
allowed for random integration of SB transposon targets
into the genome of HEK293 cells, which in turn were
targeted by the chimeric Gal4-PB. The host repair machin-
ery can be used to uptake fragments of exogenous DNA
sequences into cells and integrants can be isolated follow-
ing selection. However, this process is relatively inefficient
and only the sequence for the selection marker is required
for cell survival. In order to ensure that an intact sequence
was efficiently integrated at a large number of genomic
loci, we used the SB system for transposition of the
UAS target. By using this approach we avoided the pos-
sibility of PB recognizing its own TREs and consequen-
tially excising the target transposon. We used the two
plasmid SB approach in which the recipient transposon
contained the mammalian selection gene hygromycin
and the UAS site flanked by TTAA-rich regions on one
plasmid, as well as the SB11 transposase encoded on a
second plasmid (Figure 2A).
HEK293 cells were transfected with both SB plasmids
and stable lines were obtained after 4 weeks of culture
under hygromycin selection. Two stable polyclonal expan-
sions of HEK293 cell lines harboring the SB UAS trans-
poson were transfected with delivery plasmid expressing
N- or C-terminal Gal4-fused PB transposases or the native
PB transposase. As with the plasmid into plasmid experi-
ment, these delivery plasmids integrated a PB transposon
containing the antibiotic resistance gene neomycin and
conferred G418 resistance. Genomic DNA was isolated
from 6 replicates each for the 3 experiments. To demon-
strate the requirement of the UAS for Gal4-directed tar-
geting, control transfections with a SB recipient
transposon plasmid that lacked the UAS target sequence
were performed, and hygromycin resistant HEK293 cells
were subjected to a second round of transfections with the
PB delivery plasmids described above.
In order to detect targeted genomic insertion we used
nested PCR with the forward set of primers complemen-
tary to the PB transposon and the reverse primers extend-
ing from the SB transposon target (Figure 2A and B). As
expected, we did not obtain any PCR products from the
UAS-negative control samples indicating that neither Gal4
fusion, nor native PB transposase targeted the SB recipient
transposon alone (Figure 2D). Furthermore, we did not
detect any targeted PCR products for the 6 UAS-positive
cell populations that had been transfected with native PB
control transposase. In contrast, for all UAS-positive
populations tested with a Gal4-PB fusion, nested PCR
products were obtained and sequenced (Figure 2B).
Within the 8000 bp region that we analyzed, all 49
unique integrations recovered, localized within 1300 bp of
the UAS site with the vast majority (96%) found <800bp
up- or down-stream from the UAS (Figure 2C and
Table 2). About 95% of sequenced PCR product bands
were verified SB transposon insertions; the remaining 5%
resulted from non-specific primer binding. Both N- and
C-terminal fusions displayed a similar targeting efficiency
and the integration profile within the TTAA-rich region
flanking the UAS site appeared somewhat random
without a predictable integration distance from the UAS.
We also identified a number of hot spots where the same
insertion site was found across multiple samples; seven
sites that were targeted three or more times and for one
site, 193bp upstream of the UAS site, we detected a total
of four integrations by both nGal4–PB and PB–cGal4.
Furthermore, eight loci shared integrations from both
fusion constructs (Figure 2C).
Transposon copy number and off-target analysis
In order to assess the number of possible transposon
targets per cell, monoclonal expansions were established
from HEK293 cells, transfected with both SB and PB
transposons as described above. Individual clones from
nGal4–PB, PB–cGal4 and native PB samples were sub-
jected to Southern blot (n=1) and qPCR (n=5 each)
analysis. All samples tested contained either one or two
UAS–SB transposons (Figure 3A). We additionally
analyzed the number of PB-mediated integrations per
clonal sample by qPCR. Here, the majority contained
three to five delivery transposons with an average
number of seven integrations per cell (Figure 3B).
The protein levels of PB, nGal4–PB and PB–cGal4 were
determined by western blot (Supplementary Figure S1).
Both fusion proteins expressed at similar levels and ran
at a higher molecular weight than native PB. The ability
to form G418R colonies in a standard colony count assay
(58) was used to estimate transposase efficiency. The three
constructs produced similar numbers of colonies with a
slight reduction in efficiency for nGal4–PB compared
with native PB control (Supplementary Figure S2) recon-
firming that the Gal4 fusion did not inactivate the PB
transposase.
Non-restrictive LAM PCR can be used to amplify
genomic sequences flanking known insertion cassettes
such as transposons to identify off-target insertion sites.
Single-stranded adaptors were ligated onto linear PCR
products made from primers designed to extend away
from the TREs of the PB delivery transposon. Nested
PCR was used to amplify the TRE–gDNA junction and
products were subjected to 454 pyrosequencing. Verified
insertion sites included TRE sequence followed by the
TTAA tetranucleotide followed by genomic sequence
(Figure 3C). Four independent transfections for each of
Table 1. Distances of recovered plasmid into plasmid insertions sites
from UAS targets
Plasmid
to Plasmid
N-terminal
Gal4 PB (%)
Native
PB (%)
C-terminal
Gal4 PB (%)
insertions< 800 bp from UAS 87**** 59 77**
insertions< 250 bp from UAS 47*** 21 32*
Both N- and C-terminal Gal4 PB fusion constructs significantly biased
integration near the UAS compared with native PB by the Fisher’s
exact test. *P=0.05, **P=0.01, ***P=0.005, ****P=0.002
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AB
C
D
Figure 2. (A) Schematic for the genomic DNA targeting experiment. Helper-independent pmGENIE plasmids containing both the delivery trans-
poson, as well as the PB coding sequence were used in both the plasmid into plasmid and genomic targeting experiments. The neomycin gene is
driven by both bacterial (pBLA) and eukaryotic (SV40) promoters. Sleeping Beauty and the SB recipient transposons were encoded on different
plasmids. The recipient transposon harboring the UAS target was first integrated into gDNA by SB and stable integrants were selected with
hygromycin. A second transfection was performed with the pmGENIE delivery plasmid containing both the PB transposase and the PB transposon
with the neoR gene. Insertions by the chimeric Gal4–PB transposase that had been directed to the vicinity of the UAS target (red lines) were detected
by nested PCR (primers represented by black arrows). Black vertical lines represent actual distances of insertions recovered from the UAS on the SB
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the three experiments were pooled and analyzed using
published human genome annotations. A total of 66 414
integration sites were recovered from the nrLAM
sequencing, many of which were repeated reads indicating
good sequencing coverage. In total, 7004 of the integra-
tion sites were aligned to unique genomic locations. An
off-target analysis was performed on the integration sites
identified from the 12 polyclonal samples confirming
previous integration profiles for PB reported by us and
others (Figure 3D) (53,54,70–74). PB showed a slight pref-
erence for integration near the 50-end (within 10 kb of
transcriptional start sites) and 30-end (within 10 kb of
polyA sites) of genes, as well as a preference for introns,
possibly due to the large size and number of TTAA sites
found within introns. The frequencies of insertions re-
covered within known genes can be found in Table 3.
When compared with viruses such as HIV, PB displayed
a more random insertion site distribution and targeted
genes much less frequently (71–73). However, PB-
mediated insertions into genes were significantly more
common when compared with a random insertion pattern.
Gal4 PB biases integrations near endogenous Gal4
recognition sites
A comparison of off-target integrations for the three con-
structs revealed that the nGal4–PB sample profile was
shifted; we observed an increased number of integrations
into exons, polyA sites and transcription start sites, pre-
sumably because of altered preference of integration due
to Gal4 binding (Figure 3D). To estimate the efficiency of
the Gal4–PB fusion protein’s ability to insert near en-
dogenous Gal4 recognition sites, we annotated the
56 898 UAS-like sites found in the human genome and
examined insertions that were located in the vicinity of
these sites. Gal4 binds tightly to a specific 6 bp binding
site defined as CGGNNNNNNNNNNNCCG. Sequence
variability or alterations in the number of variable (N)
basepairs greatly reduces binding affinity (75). We
counted the number of insertions that occurred in 20 bp
increments from 0 to 10 000 bp from each Gal4 recogni-
tion site. About 32% of nGal4–PB transpositions landed
within 1.8 kb of endogenous Gal4 sites compared with 8%
for native PB and 23% were within 0.8 kb compared with
5% for native PB (Figure 3D). The cumulative percentage
of integrations recovered (Figure 3E) dramatically
increases up until 1800 bp for nGal4–PB but not for
PB–cGal4 or native PB. A histogram displaying the per-
centage of total integrations that occurred within 400 bp
intervals shows increased insertions recovered in regions
up to 1800 bp from Gal4 sites for nGal4–PB but not for
PB–cGal4 or native PB (Figure 3F). While PB–cGal4
targeted the exogenous UAS–SB transposon almost as
efficiently as nGal4–PB, we were surprised to find no pref-
erential targeting of the endogenous consensus sites by
PB–cGal4, which had an overall integration profile that
resembled that of native PB.
DISCUSSION
Traditionally, integrating vectors such as viruses have
been used to insert transgenes semi-randomly and have
led to deleterious effects due to integration at unwanted
sites (76,77). To address this problem we have designed
novel proteins encompassing the classical Gal4 DBD
fused to a PB transposase in an attempt to bias genomic
insertion to specific sites within the genome. We have
demonstrated targeting to UAS recipient plasmids in
human cells using a tethered Gal4–PB and shown that
integration preferentially occurs near the UAS recognition
sequence (Table 1). Gal4 is a tight binding Zn2/Cys6 zinc
finger with a 6 bp binding site that occurs not only in our
inserted UAS sites, but also at many endogenous human
loci (75). Despite the numerous target sites for Gal4, we
were successful in showing that genomic targeting can be
achieved near introduced target UAS sites. It is important
to assay transpositional events that occur on genomic
DNA because histone-associated DNA may influence
transposition as compared with naked DNA. Hence, we
stably introduced our recipient transposon to ensure that
the subtleties of the genomic environment could be
accounted for during Gal4-directed transposition.
In our experiments merely integrating SB transposons
containing TTAA sites without a UAS was not sufficient
for Gal4–PB targeting. Both the UAS recognition
sequence, as well as the Gal4 DBD fused to the PB
transposase were required for enhanced genomic targeting
(Figure 2B and D; Table 2). It should be noted that during
the preparation of this publication, a similar methodology
Figure 2. Continued
transposon. UAS-F and TTAA-R served as positive control primers to verify the presence of the SB transposon target. (B) Evidence for genomic
targeting and the requirement of Gal4. Genomic DNA from hygroR/G418R cell populations transfected first with SB11 and UAS–SB transposon
then next with delivery plasmids containing PB, PB–cGal4 or nGal4–PB was isolated and analyzed by PCR. Shown is a representative gel displaying
4 of 6 independent samples, each of nested products recovered for both Gal4 fusions but not native PB. (C) Schematic map of the UAS–SB target
transposon showing integrations of piggyBac donor elements using the Gal4–PB chimeric transposase. Open circles and closed triangles represent
insertions by C-terminal and N-terminal Gal4–PB, respectively. The vertical numbers represent the nucleotide location of targeted TTAA sites on the
UAS–SB transposon. The UAS was flanked on both sides by 65 TTAA sites spaced 10 bp apart. (D) Evidence for the requirement of the UAS.
Stable cells transfected with the UAS-negative SB recipient transposon were re-transfected with PB delivery plasmids. Shown is a control gel
displaying PCR products for positive control UAS F/TTAAR but not products from targeting primers for two native PB samples and both
Gal4 fusion samples (HI-LO DNA Marker, Bionexus).
Table 2. Total genomic insertions into the SB recipient transposon
recovered by nested PCR
HEK 293
Cell Line
N-terminal
Gal4 PB
Native
PB
N-terminal
Gal4 PB
UAS+ 28 0 21
UAS 0 0 0
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Figure 3. (A and B) Copy number assays for number of SB and PB transposon integrations. The gDNA from 5 single clones each for N- and
C-terminal Gal4 fusion and native PB experiments was analyzed by duplex Taqman real-time PCR. The numbers above the bars represent the
estimated copy number for each sample. The Southern blot shown on the right of each graph was applied as a standard of known number of
transposon integrations and was used to calibrate the qPCR data. (C) Sequences recovered from a representative sample showing the PB TRE on the
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was published. In that publication the PB transposase was
fused to CHK2-ZFP to direct integration (78). However,
of the targeted single clones that were isolated in that
study, >20% of negative control clones showed evidence
of native PB targeting into SB transposon targets contain-
ing the CHK2 recognition sequence. We did not observe
such insertions in our negative control experiments, which
was expected because it seems unlikely that an unmodified
PB would preferentially integrate into one of the <200
TTAA sites found on a SB transposon target given the
>10 million possible TTAA sites available in the human
genome. Currently, the discrepancy between these studies
is unclear.
Given that there were only 1–2 inserted exogenous UAS
targets per cell (Figure 3A) but millions of available
TTAA sequences throughout each cell’s genome, it is
remarkable that we have been able to detect a bias for
targeted transgene insertion. In this study, both N- and
C-terminal Gal4 fusions but not native PB preferentially
integrated within 800 bp of the UAS site. This information
could prove important in the future design of alternative
DBD–PB fusion proteins. Despite the even distribution of
TTAA sites in the regions flanking the UAS site, one every
10 bp, certain hot spots were targeted frequently. A
possible explanation for this observation is that the
physical structure of the DNA places restraints on some
of the potential integrations, whereas other TTAA sites
are more readily available for transposition. If indeed
this is the case, this phenomenon may explain why the
same sites were targeted in repeated transfections with
the same plasmid and why the N-terminal fused PB
transposase shared hotspots with C-terminal modified
PB (Figure 2C).
An extensive off-target analysis using nrLAM PCR and
454 pyrosequencing revealed that fusing the Gal4 DBD to
the C-terminal of PB, in contrast to an N-terminal fusion,
did not significantly modify PB’s off-target integration
profile (Figure 3D). It may be that PB retains its intrinsic
ability to bind DNA and is therefore, able to bind to one
of the many available TTAA sites within the genome,
thereby mediating off-target integration despite its fusion
to the Gal4 DBD. While the same mechanism should
apply for the N-terminal fusion of Gal4 to PB, we
noticed a different integration pattern: in addition to
targeting the UAS–SB transposon, nGal4–PB directed
integration within 0.8 kb of endogenous genomic Gal4 rec-
ognition sites, 23% of the time compared with 5% for
native PB controls, and within 1.8 kb of endogenous
sites, 32% of the time compared with 8% for controls.
Because 8% of integrations occur near Gal4 sites at
random, and the percentage of total recovered sites for
nGal4–PB is 32%, the difference of 24% represents the
percentage of targeted integrations due to the presence of
the Gal4 DBD. Given that there was an average of 7 PB
insertions per cell (Figure 3B) we estimate that, on
average, 1.7 insertions per cell (24% of 7 PB insertions)
were targeted to within 1.8 kb of a Gal4 site by nGal4–PB
and that 5.3 insertions landed at random TTAA sites. We
detected a variable number of PB insertions per cell
(Figure 3B) and recognized that it is possible to have
cells with or without any targeted insertions and with or
without any random off-target insertions. It is entirely
possible that the targeting efficiency would be reduced,
should the number of available recognition sites be
decreased. Because the Gal4-fused PB transposase
remains functionally active, there may be a higher prob-
ability of encountering and inserting at a random
off-target TTAA site before a TTAA site near a single
unique recognition sequence. Further experiments are
needed to determine the level of influence of the number
of possible target sequences in relation to the targeting
efficiency of a DBD–PB fusion.
It is not evident to us why nGal4–PB but not PB–cGal4
targeted endogenous sites so much more effectively. The
protein levels for the two transposases are comparable
(Supplementary Figure S1) and the efficiency of integration
for nGal4–PB was not higher than PB–cGal4 (Supple-
mentary Figure S2). It is possible that this phenomenon
may be due to spatial/steric interactions between Gal4
and PB. For example, in the N-terminal Gal4–PB configur-
ation the linker and PB transposase extend from the
C-terminal side of the Gal4 DBD. This configuration is
Figure 3. Continued
left in bold, TTAA and flanking sequence on the right. The top 2 lines with flanking sequence in blue show nested PCR products that align to the
genomic UAS–SB recipient transposon. The bottom four lines with flanking sequence in black show recovered nrLAM and 454 sequences repre-
senting off-target events with alignments to various locations in the human genome. (D) The frequency of insertion sites recovered from nrLAM PCR
that land within introns and exons, within a 10 kb window surrounding transcriptional start sites (50-end) or polyA termination sites (30-end), and
±1.8 kb and ±0.8 kb of endogenous Gal4 recognition sites. (E) The cumulative percentage of total integrations from 0 to 2400 bp from endogenous
recognition sequences. The frequency of insertions for native PB and PB–cGal4 increased linearly. nGal4–PB insertion frequency increased loga-
rithmically until 1800 bp and then increased linearly. (F) Histogram displaying the percentage of total integrations that occurred within 400 bp
intervals from 0 to 10 000 bp from endogenous Gal4 recognition sequences. The black line represents the best fit curve for nGal4–PB.
Table 3. Frequencies of integration into intragenic regions and
transcriptional start sites of RefSeq genes
Genomic location Integrations (%)
Randoma PB PB–c
Gal4
nGal4–
PB
HIVa,b,c
In RefSeq genes 33.2 60.8 57.8 61.5 83.4
±5kb from start site 5.4 19.9 19.9 39.9 11.4
Frequency of off-target integrations into genes and regions near tran-
scriptional start sites, recovered from nrLAM PCR, compared with
random and viral integration. Results from this study are boldfaced.
aValues from the work of Yant et al. (72).
bAdjusted values from the work of Narezkina et al. (71) and reported
in Yant et al. (72).
cAdjusted values from the work of Schroder et al. (73) and reported in
Yant et al. (72).
HIV, human immunodeficiency virus.
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similar to the orientation of the natural activation domain
in the full length wild-type Gal4 protein. However, this
model of favorable fusion architecture does not explain
why both fusions to the PB transposase apparently target
the exogenous UAS on the SB transposon with similar
efficiency; neither does it explain why both constructs are
able to integrate near the UAS on recipient plasmids. One
explanation could be that PB–cGal4 may only efficiently
bind naked DNA such as episomal plasmids. Exogenous
UAS sites were chromatinized, however, and PB–cGal4
retained the ability to target these sites, indicating that
PB–cGal4 can bind DNA associated with histones. An
alternative explanation for the difference in exogenous
targeting between the N- and C-terminal fusions is that
the introduced UAS sequence, like classic UAS sequence
arrays, is made up of repeated Gal4 recognition sequences,
and that the C-terminal fusion requires a number of sites in
tandem for efficient binding. It is possible that, in addition
to binding to UAS arrays, the N-terminal fusion also effect-
ively binds endogenous monomeric Gal4 recognition
sequences.
Although both chimeric proteins were effective in biasing
integration toward exogenous or endogenous Gal4 binding
sites, the number of off-target integrations identified in this
study remains high and points to the need for a system
where the binding of a specific DBD is a prerequisite for
PB-mediated transposition. It may be possible to achieve
this by mutational molecular evolution in which the activ-
ity of the PB protein is made to be dependent on its DBD.
Redesign of the dimerization interface of ZFNs has
reduced off-target toxicity by reducing binding of the
protein dimers in solution (79). Perhaps mutations in
PB’s dimerization domain could inhibit activity in
solution but retain the ability of the protein to dimerize
and integrate, should the dimers unite at a DBD target
sequence. It is clear that modifications such as this will be
necessary for the chimeric PB strategy to mature into a
viable method for genetic engineering and therapy.
-C31 integrase mediates efficient DNA delivery to re-
cipient plasmids using site-specific recombination between
its attP and attB recognition sites and to pseudo attP sites
of which there is an estimated 370 in the mammalian
genome. A study looking at 196 independent genomic in-
tegration events revealed that 80% of insertions occurred
near -C31 attP sequence motifs, with 7.5% of integra-
tions at a unique site on chromosome 19 (80). Unfortu-
nately, a high proportion of cells expressing -C31
integrase were found to have numerous chromosomal
abnormalities including various translocations (80,81).
The adeno-associated virus (AAV) is able to insert its
genome into a specific site on chromosome 19 (AAVS1)
through the activity of its Rep78 protein. Hybrid adeno-
virus/AAV vectors have been developed to target trans-
genes to this site (82). Co-infection of human
hematopoietic cells with two helper-dependent adenovirus
vectors containing the rep78 gene on one vector and a
GFP reporter on the second resulted in 30% of integration
into the AAVS1 region (83).
Gersbach et al. (84) recently described zinc-finger
recombinase (ZFR) fusion proteins with high specificity
in targeting and with few off-target consequences (84).
This group was able to efficiently integrate transgenes
into a specific target sequence harbored on PB transposons
randomly integrated within the genome. The utility of this
approach, however, is hindered by the necessity to intro-
duce target sites into the genome of interest due to the fact
that the catalytic domain of the integrase retains strict
sequence specificity for its native recognition sequence.
The plasmid-based PB system has many advantages over
viral techniques including tolerance by the immune system,
large cargo capacity, as well as inexpensive and simple prep-
aration. PB was shown to tolerate an assortment of fusion
domains (50,55,65) while retaining high integration
efficiencies. Unlike recombinase-based approaches, which
are restrained by a specific DNA-binding sequence, it
should be possible to replace Gal4 with any custom DBD.
In order to reduce the number of off-target integrations, a
DBD with a unique 18 bp+recognition sequence could be
used to tailor targeting of the chimeric transposase to
virtually any pre-defined genomic site.
The need for highly specific endogenous integration is
paramount and our future focus is to explore the use of
highly specific DBDs to target a natural safe harbor in
the human genome. One of the advantages of this
strategy would be the ability to isolate single clones with
safe single targeted insertions for use in awide variety of cell
replacement therapies. By expanding clones and verifying
both the presence of a targeted insertion and the absence of
multiple insertions, it would be possible to control gene
silencing resulting from position effects and provide a
means for avoiding detrimental mutations. The current
study has laid the groundwork for using DBD–PB
transposase fusion proteins for directed genomic integra-
tion. We anticipate that further improvements to this ver-
satile frameworkwill ultimately permit researchers to safely
target a genetic cassette to any location within the genome.
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